Diasome Pharmaceuticals
Cleveland
About Diasome Pharmaceuticals
Diasome Pharmaceuticals is a clinical stage diabetes therapeutics company that designs and develops insulin-based therapies. The company’s products include Oral HVD-I, a targeted oral insulin in a pill or gel cap dose form; HDV-I, an injectable short acting insulin; and HDV-B, an injectable basal long acting insulin. It develops products for patients suffering from Type 1 and Type 2 diabetes. Diasome Pharmaceuticals was founded in 2004 and is based in Conshohocken, Pennsylvania.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $92.0M
- Last round: Series Unknown (Jun 2023)
- Website: diasome.com
- Phone: 216-444-7110
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/diasome-pharmaceuticals-120204 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.